1. European Medicines Agency, 2017. Guideline on good pharmacovigilance practices (GVP) – Module VI (Rev 2) EMA/873138/2011 Rev 2. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports_en.pdf (accessed 5 May 2020).
2. European Medicines Agency, 1995. ICH Harmonised Tripartite Guideline E2A. https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-15.pdf (accessed 5 May 2020).
3. Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19
4. The COVID-19 pandemic and the use of MS disease-modifying therapies